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Abstract
MicroRNA-208a is a cardiac specific oligo-nucleotide. We aimed at investigating the ability of microRNA-208a to diagnose
myocardial infarction and predict the outcome of primary percutaneuos coronary angiography (PCI). Patients (n = 75) presented
by chest pain were recruited into two groups. Group 1 (n = 40) had ST elevation myocardial infarction (STEMI) and underwent
primary PCI: 21 patients had sufficient reperfusion and 19 had no-reflow. Group 2 (n = 35) had negative cardiac troponins (cTns).
Plasma microRNA-208a expression was assessed using quantitative polymerase chain reaction and patients were followed for
occurrence of in-hospital major adverse cardiac events (MACE). MicroRNA-208a could diagnose of MI (AUC of 0.926). After
primary PCI, it was superior to cTnT in prediction of no-reflow (AUC difference of 0.231, P = 0.0233) and MACE (AUC
difference of 0.367, P = 0.0053). Accordingly, circulating levels of miR-208a can be used as a diagnostic marker of MI and a
predictor of no-reflow and in-hospital MACE.
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Abbreviations
CABG coronary arteries bypass grafting
cDNA complementary DNA
CK-MB creatine kinase MB




hs-Tns high sensitivity troponins
MACE major cardiac adverse events
MI myocardial infarction
miR microRNA
PCI percutaneuos coronary angiography
qRT-PCR quantitative real time polymerase chain reaction
SPSS statistical package for social sciences
STEM ST elevation myocardial infarction
TIMI thrombolysis in myocardial infarction
URL upper reference limit
WBCs white blood cells
Introduction
Ischemic heart disease is the leading cause of death worldwide
[1]. Timely diagnosis of MI is critical for early initiation of
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management which is a pivotal variable of outcome.
Presenting symptoms include chest pain (with radiation to
the left arm, neck, jaw or epigastria) and/or shortness of
breath, vomiting, palpitations or syncope. The relief of chest
pain by administration of nitrates has been used for a very long
time as a diagnostic clue but it is less emphasized recently
because it may be misleading [2, 3].
In the context of the 4th universal definition of myocardial
infarction biomarkers namely cardiac troponins (cTns) repre-
sent the corner stone for diagnosis. Acute myocardial injury is
evidenced by at least one value of cTns rise above the 99th
percentile upper reference limit (URL). If associated with any
symptomatic, ECG and/ or imaging evidence of ischemia, this
will be consistent with MI type 1 [4]. Primary Percutaneuos
coronary intervention (PCI) based strategy is the recommend-
ed initial approach for MI patients. Failure to restore blood
flow to the myocardium despite physical relief of the occlu-
sion is known as no-reflow which is an independent predictor
of death and morbidities [3].
MicroRNAs (miRNAs) are regulatory, non-coding RNAs,
around 22 nucleotides in length which are involved in post
transcriptional gene regulation [5]. miRNAs are predicted to
target 60% of all genes regulating the expression of one-third
of all human genes [6]. They are released by cells into circu-
lation either passively or actively [7]. The expression level of
miRNAs can be used to guide the diagnosis of certain diseases
and predict drug responses and prognosis. miR-1, miR-133a,
miR-499, and miR-208a have been shown to be over
expressed in myocardial infarction [8, 9]. While miR-1,
miR-133a, miR-499 may be less specific to myocardial infarc-
tion, miR-208a is shown in many studies to be more specific
and may be promising as marker [10].
So, this study was designed to explore the role of miR-208a
as a marker for diagnosis of AMI as well as a predictor for
outcome of primary percutaneuos coronary angiography es-
pecially no-reflow phenomenon.
Patients and Methods
The data supporting the study findings are available from the
corresponding author upon request.
Study Population
This study was carried out in CardiologyDepartment, Zagazig
University Hospitals. Approval for the study was obtained
from institutional review board. Authors declare no conflict
of interests. The study started in January 2018 and ended in
August 2019. The study included 75 adult patients. Informed
consents were obtained from all patients to use their clinical
data and samples for research and analysis according to the
guidelines of the Declaration of Helsinki.
Patients admitted within 12 h of the onset of chest pain
were enrolled. Exclusion criteria included recent myocardial
infarction, previous coronary arteries bypass grafting surgery
(CABG), or PCI within 1 week, congestive heart failure or
cardiogenic shock at time of presentation, regular hemodialy-
sis and/or ongoing malignancy. Patients were classified into 2
groups: Group 1 included 40 patients diagnosed with STEMI
and underwent primary PCI and Group 2 included 35 cases
with chest pain but negative troponin T (cTnT). Group 1 is
subdivided into: subgroup (a) including 21 cases with suffi-
cient reperfusion (thrombolysis in myocardial infarction TIMI
III, TIMI II) and subgroup (b) including 19 cases with insuf-
ficient reperfusion (TIMI I, TIMI 0). Both study groups were
subjected to detailed history taking and clinical examination.
The patients were followed for occurrence of major adverse
cardiac events (MACE) during hospital stay (3 days average).
Blood Samples
Samples for routine investigations and myocardial injury bio-
markers were collected and handled according to instructions
of hospital laboratories service manual. For miRNA determi-
nation, 3 mL fresh blood was aspirated from antecubital veins
of study population at first presentation prior to PCI and de-
livered into sterile plain vacutainer tubes. Tubes were centri-
fuged for 10 min at 12000 g and miRNA was extracted from
the serum immediately afterwards as described below.
Measurement of cTnT Levels
Cardiac Troponin T levels were measured in patients’ serum
by electrochemiluminescence using Roche Cobas-
e411automated analyzer using Roche Elecsys® Troponin-T-
HS kit.
Quantification of Circulating miR208a
Serum expression of miR-208a was assessed using quantita-
tive real time polymerase chain reaction (qRT-PCR). miRNA
extraction was done using “miRNeasy Mini kit“(Qiagen,
Germany) according to the supplier protocol and DNA con-
tamination was checked spectrophotometrically by measuring
ratio of 260/280 absorbance. For reverse transcription of
miRNA “miScript II RT Kit” (Qiagen, Germany) was used
according to the supplier protocol. Complementary DNA
(cDNA) was then incubated at -80 °C. Amplification and de-
tection by real time PCR was performed using target specific
“miScript “Primer Assays (forward primers) and the “miScript
SYBR Green PCR Kit “(Qiagen, Germany) according to the
supplier protocol. Fold changes of miRNA expression were
calculated using the formula: Fold Change = 2^ –ΔΔCT [11].
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Statistical Analysis
The acquired data were analyzed usingMicrosoft Office Excel
2007 and Statistical Package for Social Sciences version 24
(SPSS: An IBM Company). Data are presented as mean ±
Standard deviation (SD) for normally distributed data other-
wise range and median are used. Normal distribution of data
was confirmed by Shapiro-Wilk test. For comparison of
groups, the Mann-Whitney test, Pearson χ2 test or the
Student t test was performed. Diagnostic/Prognostic
Performance of tests was done using receiver-operating curves
(ROC), AUC comparison was done using the Delong et al.
method [12], while the cut-off values were calculated using
the Youden J statistics [13]. McNemar’s test was used to com-
pare the diagnostic performance of miR-208a to hs-cTnT. The
threshold of significance was fixed at 5% level (p value),
where P values <0.05 indicate significant results.
Results
The patients’ characteristics are shown in Table 1. The two
study groups are homogenous in terms of demographic data,
risk factors and history with no significant difference. None of
the candidates of both groups was known to have
hyperlipidaemia. Those who had previous infarction and/ or
revascularization; whether PCI or CABG; were clinically free
of events for more than 2 months before admission. The white
blood cells (WBCs) count was found to be significantly higher
in the patient group as well as the routine cardiac biomarkers.
There was no statistically significant difference in the rest of
clinical and routine laboratory findings.
miR-208a was significantly up-regulated in STEMI pa-
tients compared to control group (miR-208a fold change me-
dian = 32.54, range: 11.51–88.91). ROC analysis of relative
expression values shows that miR-208a has reasonable sensi-
tivity and specificity for MI diagnosis (AUC = 0.92, sensitiv-
ity = 92.5, Specificity = 80). The diagnostic performance of
miR-208a is comparable to the routine cardiac biomarkers;
creatine kinase-MB (CK-MB) (area difference 0.0439, P =
0.235) and cTnT (area difference 0.0614, P = 0.06) (Fig. 1-
a). McNemars’ test shows that miR-208a diagnostic power is
similar to hs-cTnT (p = 1.000).
The STEMI subgroups were found to be homogenous in
terms of demographic data, risk factors and history.
Subgroups’ characteristics are shown in Table 2. No signifi-
cant difference in clinical findings at time of presentation was
noticed. miR-208a was significantly over expressed in sub-
group (b) compared to subgroup (a) (Table 2, Fig. 2). ROC
analysis of miR-208a expression in patients’ subgroups shows
Table 1 Characteristics of
patients Group 1 (n = 40) Group 2 (n = 35) P value
Mean ± SD Mean ± SD
Age, y 57.37 ± 12.47 60.2 ± 11.1 0.25
Male sex, n (%) 30 (75%) 28 (75%) 0.605
Current Smoker, n (%) 27 (67.5%) 19 (54.3%) 0.2411
Hypertension, n (%) 16 (40%) 14 (40%) 1.0000
Diabetes, n (%) 19 (47.5%) 18 (51.4%) 0.8230
Family history, n (%) 4 (10%) 3 (8.57%) 0.8325
Obesity, n (%) 7 (17.5%) 4 (11.4%) 0.4584
Previous MI, n (%) 4 (10%) 2 (5.7%) 0.4949
Previous revascularization, n (%) 6 (15%) 2 (5.7%) 0.1937
Blood pressure, mmHg
Systolic 135.75 ± 18.7 129.3 ± 16.6 0.08186
Diastolic 76.25 ± 8.37 74 ± 9.37 0.23404
Heart rate, bpm 103.2 ± 18.3 105.7 ± 23.8 0.9124
Range (median) P Value
Time to admission, hours 1–5 (3) 1–7 (3) 0.5157
WBCs × 103/μL 3.5–9.9 (7.4) 2.7–9.3 (6.4) 0.0438
Hemoglobin, g/dL 16.2–10.6 (13.05) 15–10.2 (12.7) 0.5892
Platelet count, 103/μL 123–410 (264) 41–396 (248) 0.05238
CK-MB, IU/L 2–96 (58.5) 1–5.5 (2.8) < 0.00001
hs-TnT IU/L 0.01–10.5 (4.85) 0.01–0.02 (0.01) < 0.00001
CK-MB indicates creatine kinase-MB; hs-TnT, high sensitivity Troponin T and WBCs white blood cells
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it to be a good predictor of no-reflow as well as in-hospital
MACE after primary PCI and significantly superior to cTnT
and CK-MB (Tables 3, 4 – Fig. 1-b&c).
Discussion
Myocardial infarction is one of the main causes of mortality in
the world which is mainly treated with primary PCI or fibri-
nolytic drugs. Up-to-date cardiology guidelines recommend
early diagnosis and immediate mechanical restoration of cor-
onary flow and establishment of myocardial reperfusion in
patients presenting with STEMI [3]. Despite the great im-
provement in the detection of cardiac troponins; the gold
standard test in myocardial infarction; there is a decrease in
test specificity which is associated with longer stay at emer-
gency department (ED), more healthcare costs and undue in-
terventions [14]. The high sensitivity cTns (hs-Tns) essays are
less accurate in the first hour of pathology development [4].
Also, the prognostic role of hs-Tns is less well established
[15–18].
A great improvement has been encountered in the tech-
niques and materials used for primary PCI, yet it fails to nor-
malize the coronary flow and myocardial perfusion in some
patients. This phenomenon described as no-reflow is associ-
ated with an increased mortality as well as morbidity. Studies
have suggested possible mechanisms for no-reflow phenom-
enon such as endothelial ischemic damage, microvascular
Fig. 1 (a) ROC comparison of miR-208a diagnostic performance against
routine cardiac biomarkers. MicroRNA-208a is not inferior to hs-cTnT as
a diagnostic marker. (b) Receiver operating curve analysis of no-reflow
prediction performance of miRNA208a, CKMB and hs-Troponin T.
MicroRNA-208a shows significantly higher prediction of no-reflow as
compared to routine cardiac biomarkers. (c) Receiver operating curve
analysis of MACE prediction performance of miRNA208a, CKMB and
hs-Troponin T. microRNA-208a is significantly higher to routine cardiac
biomarkers in MACE prediction
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obstruction, leukocyte occlusions, mechanical compression
due to interstitial edema, reactive oxygen radicals and coagu-
lation. However, no-reflow phenomenon is still unpredictable
with no marker being suitable for anticipating no-reflow [19].
As the pathogenesis of myocardial infarction involves tis-
sue ischemia, edema and necrosis with release of necrotic
yield into circulation, miRNAs are suggested to have a prom-
ising diagnostic role [5].
In this study we report five main findings. First, the circu-
lating level of miR-208a was significantly higher in STEMI
group than the control group. Secondly, miR-208a has a good
diagnostic accuracy (AUC = 0.926). Thirdly, the diagnostic
Table 2 characteristics of
patients’ subgroups Subgroup a (n = 20) subgroup b (n = 19) P value
Mean ± SD Mean ± SD
Age, y 61.04 ± 12.11 53.32 ± 11.86 0.06
Male sex, n (%) 16 (76.19%) 14 (73.68%) 0.855
Current Smoker, n (%) 13 (61.90%) 14 (73.68%) 0.427
Hypertension, n (%) 8 (38.09%) 8 (42.11%) 0.796
Diabetes, n (%) 9 (42.85%) 10 (52.63%) 0.53645
Family history, n (%) 2 (9.52%) 2 (10.53%) 0.9159
Obesity, n (%) 6 (28.57%) 1 (5.26%) 0.05269
Previous MI, n (%) 3 (14.28%) 1 (5.26%) 0.316443
Previous revascularization, n (%) 5 (23.80%) 1 (5.26%) 0.100914
Blood pressure, mmHg
Systolic 139.29 ± 16.9 131.84 ± 20.22 0.212724
Diastolic 77.62 ± 7.68 74.74 ± 9.05 0.282966
Heart rate, bpm 1–5 (3) 1–5 (2) 0.152914
Range (median) P
Time to admission, hours 1–5 (3) 1–7 (3) 0.5157
miR-208a Fold change* 11.51–56.66 (26.43) 17.92–88.90 (53.60) < 0.0001
*Cut-off value for change in expression is 1. Values >1 indicate up-regulation, while values <1 indicate down-
regulation
miR-208a indicates microRNA-208a
Fig. 2 Box plot of the fold change
values of miR-208a in subgroup a
(21 patients with TIMI III, TIMI
II flow after primary PCI) and
subgroup b (19 patients with
TIMI I, TIMI 0 flow after primary
PCI)
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accuracy of the studied miRNA is comparable to that of the
routine cardiac biomarkers including CK-MB and hs- TnT.
Fourthly, miR-208a showed good performance in prediction
of in-hospital MACE which was significantly superior to CK-
MB and TnT. Finally, miR-208a showed good performance in
prediction of no-reflow.
The time from onset of chest pain till admission and
obtaining samples in our study was 1–5 h for the STEMI
group and 1–7 h for the control group. While very few studies
on miRNAs in myocardial infarction reported the time to ad-
mission we find that Devaux et al. reported significantly lon-
ger times to admission which were 3–14 h for the STEMI
group and 3–12 h for the control group [20]. Almost all studies
that followed the temporal profiles of miRNAs in myocardial
infarction reported them to be detected within the first hour of
infarction, peaks early, drop after primary PCI to be nearly
undetectable in circulation by discharge time [21–25]. The
later presentation of the patients in the study by Devaux
et al. may explain the less promising results they reported.
While we did not intend to choose shorter periods of onset
of symptomswhile recruiting our patients to the study, we find
this parameter to be more in line with our vision for the pos-
sibility of future use of miR-208a for two reasons. First, most
of the recent guidelines and studies for best clinical practice
recommends early rule in/out of infarction within 1 h of pre-
sentation. From health economics and clinical points of view
this is more convenient [26]. Secondly, the accuracy of hs-Tns
assays increases with longer periods from onset of symptoms
which makes it extremely difficult for any other biomarker to
compete with and may be not worth investigating, but its role
in the first hour of onset of symptoms is still controversial [4].
The STEMI group had a significantly higherWBCs counts
in comparison with the control group. This finding could re-
flect active inflammatory process linked to the acute MI and is
concordant with other reports [27]. Meder et al. showed no
difference in WBCs count which may be attributed to the
small sample size they used [28]. Although this finding may
be considered as just an ancillary finding, from the molecular
pathology point of view it may be linked to the role of miR-
208a in regulating cell proliferation and migration and we
think it warrants further investigation [29, 30]. It is of note
that miR-208a is known to be cardiomyocyte specific and not
expressed by leukocytes [31].
Our study shows significant higher concentrations of miR-
208a in the STEMI group in comparison to the control group.
Similar findings were reported by Devaux et al. 2015, Liu
et al. 2015 and Liu et al. 2017 [23, 32, 33]. The diagnostic
performance of miR-208a is still controversial. In our study it
showed good performance with AUC of 0.926 which is com-
parable to that reported by Li et al. 2013 andWang et al. 2010.
However, Devaux et al. 2015 and Liu et al. 2015 reported
lower diagnostic power of the marker with AUC of 0.76 and
0.72; respectively. In the study by Devaux et al. 2015, this can
be attributed to the later time of presentation while we suspect
that the methodology used by Liu et al. 2015 is the cause as
they had their samples frozen before extracting the RNA and
this usually gives less accurate results [10, 20, 22, 33].
It has finally to be noted that for most of the aforemen-
tioned studies, miRNA performance is compared between
STEMI patients and healthy control group. Our study is one
of very few studies which compared STEMI patients to a
control group of unstable angina. This makes our findings in
the diagnostic context more valuable. Several studies have
suggested the use of miR-1, miR-16, miR-499 and/or miR-
133a as a standalone or combined diagnostic tests of MI [10,
20–22]. While some of the aforementioned markers showed
good sensitivity, most of them lack specificity and are of low
diagnostic power compared to the cardiac troponins.
In this study, miR-208a showed very good performance as
a prognostic marker. It can predict in hospital MACE with
good accuracy (AUC = 0.871). Supporting results were re-
ported by Gidlöf et al. and Widera et al. [21, 34]. While these
studies showed troponin to be superior as MACE predictor,
our study shows miR-208a to be superior to both CK-MB and
cTnT. This may be attributed to two main factors; the very
early time of presentation of patients enrolled in this study in
Table 3 miRNA-208a prognostic
performance Cut-off (>) AUC Sensitivity Specificity 95% CI p value
No-reflow 42.94 0.875 73.68 95.24 0.732 to 0.958 < 0.0001
MACE 32.54 0.871 83.33 86.36 0.727 to 0.956 < 0.0001
MACE indicates major adverse cardiac events
Table 4 Comparison prognostic performance of miR-208a and routine
biomarkers
miRNA 208a
Areas difference 95% CI P
No-reflow hs-Troponin I 0.231 0.0314 to 0.430 0.0233
CK-MB 0.257 0.0625 to 0.451 0.0096
MACE hs-Troponin I 0.367 0.109 to 0.626 0.0053
CK-MB 0.323 0.135 to 0.511 0.0008
CK-MB indicates creatine kinase-MB; hs-TnI, high sensitivity Troponin
I; MACE, major adverse cardiac events and miR-208a, microRNA-208a
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comparison with other studies and the short term period of
follow up of patients for MACE; only during hospital stay
(average 3 days). CORTEZ-DIAS N et al. studied the short
and long term prognostic value of some miRNAs including
miR-208a but they did not clearly discuss the value of miR-
208a in predicting short term prognosis [35].
To the best of our knowledge, this is the first study to
investigate the value of miR-208a in no-reflow phenomenon
and the second to investigate the role of any knownmiRNA in
no-reflow. Only one article addressed the value of miR-30e in
no-reflow prediction, where Su et al. found this marker to be
an independent predictor of no-reflow [36]. In our study, miR-
208a is proved to be a good predictor of no-reflow with sig-
nificantly higher plasma levels in patients with TIMI I or TIMI
0 flow after primary PCI. miR-208a has good prognostic per-
formance with AUC = 0.871 which is significantly better than
that of routine cardiac biomarkers. According to literature, we
doubt the specificity of miR-30e and believe that miR-208a is
more specific and reliable, but still real experimental evidence
is needed.
The current study had few limitations. All the studied sub-
jects were presented to the ED with chest pain and had signif-
icant ECG changes; this explains the overestimated AUC for
troponins and makes the studied cohort less representative of
the whole population. This study did not include patients with
Non -STEMI, recent MI, cardiogenic shock or heart failure at
time of admission. Although these categories were excluded
to eliminate the possibility of them having false elevation of
miRNA levels, they may be considered for future studies. The
study included patients presented within short time from onset
of symptoms which may be viewed in two different ways. On
one hand, the reported results cannot be generalized to patients
presented at later times. On the other hand, they strengthen the
usefulness of miR-208a in early hours of infarction. Finally,
we conducted our analysis on miR-208a not miR-208b which
has a similar (but not identical) nucleotide sequence to miR-
208a. Many studies have investigated either miR-208a, miR-
208b or both. Accordingly, we would suggest extending fu-
ture studies to include both sequences for comparison of their
diagnostic and prognostic performance.
Conclusion
The present study highlights the value of miR-208a as a diag-
nostic and prognostic marker in patients presented with
STEMI. It is a good marker for diagnosis of STEMI and pre-
diction of no-reflow and in-hospital MACE after primary PCI.
Although still far from clinical application due to long time
needed for the assay (at least 2 h) yet the introduction of new
fast technologies for nucleic acids assays could support its
application in clinical sittings. We recommend extending the
study to include large cohort of population, including all
categories of acute coronary syndromes, follow up of patients
for longer time and temporal profiling of the marker. A more
in depth study to consider the extent of cardiac damage and
the infarction territory may be pursued.
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